He was judged to be in the intermediate risk category by the International Metastatic Renal Cell Carcinoma Database Consortium risk group classification.ĬT#3 continued to show lung metastases with an increase in the number of lesions compared to CT#1‐2. Hemoglobin concentration (16.3 g/dL), neutrophil count (4692/µL) and platelet count (246 × 10 3/µL) were normal. Laboratory findings, including serum levels of thyroid‐stimulating hormone (TSH, 2.9 µIU/mL), triiodothyronine (2.66 ng/mL), thyroxine (0.89 µg/dL), aspartate aminotransferase (AST, 19.0 U/L), alanine aminotransferase (ALT, 15.0 U/L) and calcium (9.9 mg/dL, were normal. Prior to receiving the treatment, the findings of a physical examination, including height (1.66m), body weight (63.4kg), and the Karnofsky Performance Status (score: 100), were normal. Yellow arrowheads indicate lung metastasis that appeared after nephrectomy
#Keynote 426 criticism plus#
CT#1, #2, #3, #4, and #20 were captured on Days #‐80 (80 days before the initiation of treatment with pembrolizumab plus axitinib), −70, −9, 87 (87 days after the initiation of treatment with pembrolizumab plus axitinib), and 1137. Pink asterisks in panels C and B indicate a renal tumor in axial and coronal views of CT#2.
#Keynote 426 criticism trial#
Pink and green arrowheads indicate lesions measured in the KEYNOTE‐426 trial (lesions #1 and #2, respectively). Representative CT images of the present case. 2A‐D, 2E‐F, 2G, 2H, 2J, and 2I indicate images in Figure 2 Blue arrowheads indicate the day of pembrolizumab administration. Pink columns indicate the dose and duration of prednisolone (initiation dose: 40mg). The adverse events shown are hyperthyroidism with abdominal pain (label: hyperthyroidism, color: green, Days #19‐47), palmar‐plantar erythrodysesthesia (PPES, light purple, Days #33‐180), maculo‐papular rash (rash, emerald green, Days #33‐180), hypothyroidism (green, #Days 47‐current), mucosal inflammation (peach, Days #54‐180), diarrhea (yellow Days #117‐271, 287‐323, 303‐323, and 509‐636), decreased appetite (orange, Days #231‐245), proteinuria (purple, Days #251‐272), pruritis (red, Days #608‐628), high alanine aminotransferase (ALT, gray, Days #629‐803), and high aspartate transaminase (AST, dark blue, Days #629‐831).
Adverse events are shown with colored columns (except for pink columns), the heights and widths of which indicate severity and duration, respectively.
Black and white dots indicate the lengths of lesions #1 and 2, respectively.
0 kommentar(er)
